On November 10, 2025, GC101 Adeno-Associated Viral Vector Injection, a gene therapy agent for spinal muscular atrophy (SMA) independently developed by Beijing Genecradle Therapeutics Co., Ltd. (hereafter referred to as "Genecradle"), was granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). This marks the third FDA ODD conferred to Genecradle, following GC301 for Pompe disease and GC310 for Wilson's disease, underscoring the authoritative recognition of the competitiveness of China-originated gene therapies in the global rare disease therapeutics landscape and offering a novel therapeutic option for SMA patients worldwide.

Spinal muscular atrophy (SMA) is an autosomal recessive genetic disorder primarily attributed to mutations in the survival motor neuron 1 (SMN1) gene, which results in deficiencies in SMN protein function, subsequent degeneration of motor neurons, progressive muscle weakness and atrophy, and life-threatening complications in severe cases. Clinical epidemiological data indicate that the carrier frequency of this pathogenic gene in the Chinese population is approximately 1 in 42, with a neonatal incidence rate of roughly 1 in 10,000. Among SMA subtypes, Type 1 SMA is the most severe: in the absence of timely and effective therapeutic intervention, the median survival time is 13.6 months, and the majority of patients succumb before reaching 24 months of age. Most Type 2 SMA patients lose independent sitting ability and develop paralysis during adolescence, with disease progression accompanied by multisystem complications including respiratory insufficiency, dysphagia, and scoliosis, often leading to death due to respiratory failure. Type 3 SMA is characterized by progressive proximal muscle weakness, with patients facing gradual loss of motor function, impaired respiratory capacity, and skeletal deformities, resulting in a substantial decline in quality of life as the disease advances. Clinically unmet needs persist in SMA treatment, necessitating the development of safer, more efficacious, and accessible innovative therapeutic strategies.

As China's first adeno-associated viral (AAV) vector-based gene therapy for SMA administered via intrathecal injection, GC101 Injection was designed to address key clinical unmet needs from the outset of its development, distinguishing itself through unique technical configurations and significant therapeutic merits. Via a single intrathecal administration, the agent precisely delivers the gene encoding functional SMN1 protein into the patient's body, enabling sustained SMN protein expression, ameliorating motor neuron function at the etiological level, and exhibiting the potential for "single-dose administration with long-term therapeutic efficacy." In prior domestic clinical trials, numerous enrolled patients achieved significant milestones in motor function recovery. In contrast to conventional therapeutic modalities requiring long-term and repeated administration, GC101 offers differentiated advantages, providing SMA patients with a more convenient and clinically beneficial innovative treatment option.

Supported by robust clinical evidence, GC101 Injection was included in the Breakthrough Therapy Designation list by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China in December 2024, expediting its domestic regulatory approval and marketing process. Currently, the Phase III pivotal clinical trial of GC101 for the treatment of Type 2 SMA has completed full patient enrollment across seven leading medical institutions, including the 7th Medical Center of the Chinese People's Liberation Army General Hospital, Peking University First Hospital, Beijing Children's Hospital Affiliated to Capital Medical University, Wuhan Children's Hospital Affiliated to Huazhong University of Science and Technology, Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine, Children's Hospital of Soochow University, and Shenzhen Children's Hospital. This achievement lays a solid foundation for the domestic approval and commercialization of the drug.